Navigation Links
Lexicon to Present Clinical Data for Diabetes Drug Candidate, LX4211, at Two Major Healthcare Conferences
Date:6/15/2010

acists, podiatrists, psychologists and other health care professionals.  More than 15,000 professionals gather each year to share research, treatment recommendations and advances toward a cure for diabetes.

About LX4211

LX4211 is an orally-delivered small molecule under development as a potential treatment for diabetes. LX4211 inhibits both sodium-glucose cotransporter type 2, or SGLT2, and sodium-glucose cotransporter type 1, or SGLT1.  SGLT2 is a transporter responsible for most of the glucose reabsorption performed by the kidney.  SGLT1 is a transporter responsible for glucose and galactose absorption in the gastrointestinal tract, and to a lesser extent than SGLT2, glucose reabsorption in the kidney.  In a combined Phase 1 single ascending-dose and multiple ascending-dose study, LX4211 was well tolerated at all dose levels and produced a dose-dependent increase in urinary glucose excretion. In preclinical studies, animals treated with LX4211 demonstrated increased urinary glucose excretion and decreased blood HbA1c levels (a marker of long-term blood sugar levels).  Importantly, urinary glucose excretion returned to baseline after treatment was discontinued.

For more information on LX4211, and to access the presentations (available after June 21 and 28, 2010, respectively), please visit www.lexpharma.com.

About Lexicon

Lexicon is a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease.  Lexicon currently has four drug candidates in mid-stage development for diabetes, i
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology news :

1. Decoding the dictionary: Study suggests lexicon evolved to fit in the brain
2. Heart of Herschel to be presented to media
3. Frontiers in Optics presents scientific advancements
4. Male contraception breakthroughs to be presented, Seattle Sept. 27-28
5. New book presents successful strategies for probing genetic variation
6. NARSAD presents 2007 prizes for outstanding achievement in neuroscience and psychiatric research
7. Chemical compound present in detergents produce bacteria alterations in agricultural soils
8. New book presents methods to poke and prod individual molecules
9. Present-day species of piranha result from a marine incursion into the Amazon Basin
10. Roger Kornberg to present lecture at the Joint Biophysical Society/IUPAB Meeting
11. Internationally recognized experts presents a complete overview on hydroecology and ecohydrology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/10/2014)...  Valencell, a leader in performance biometric data sensor ... from its licensees for highly accurate, clinically validated biometric ... coming from fitness and health sectors, but first responders/military ... is only as useful as the biometric data it ... in long-term mass consumer adoption of wearable products," said ...
(Date:12/5/2014)... 4, 2014 Increased emphasis on product ... new testing and inspection technologies. The convergence of ... a range of innovative test solutions. This trend ... Y, which is generally more inclined towards communication, ... development strategies of test equipment vendors will cater ...
(Date:11/21/2014)... 2014 According to a new ... (Video, RFID, Access Control, Intrusion Detection, Parking Management, Under ... Component Service Geography - Global Forecasts to 2020", published ... to be around $25 Billion in 2014 and is ... a CAGR of 8.69%. Browse 116 market ...
Breaking Biology News(10 mins):Wearable Technology Products Demand Highly Accurate Biometric Technology 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3
... eggs in the nest of a magpie so that their ... their young are not raised together with other magpies. The ... by their foster parents are much lower, according to research ... Spain. The findings are published in Springer,s journal Behavioral ...
... time, large-scale information on the biochemical makeup of ... These molecules are used in research to help ... Making these data accessible to researchers worldwide increases ... NIH,s National Center for Advancing Translational ...
... Calif. , Dec. 11, 2013  DigitalPersona, Inc., ... today announced that the DigitalPersona ® FingerJet ... certified by the National Institute of Standards and ... program to meet the United States Government,s  Personal ...
Cached Biology News:Magpie parents know a baby cuckoo when they see one 2Gene-silencing data now publicly available to help scientists better understand disease 2Gene-silencing data now publicly available to help scientists better understand disease 3DigitalPersona FingerJet Recognition Engine Top Performer in Recent MINEX Testing 2
(Date:12/24/2014)... report expects global cell isolation and expansion market to ... carefully analyzed data about the vital drivers, restraints, trends, ... Copy of Report @ http://bit.ly/1yUxy0T , According ... will keep witnessing growth at an impressive CAGR during ... by rapid technological advancements, government funding and investments, and ...
(Date:12/24/2014)... 2014 Vermillion, Inc. (Nasdaq:   VRML), ... announced today that investors including Oracle Investment Management, ... and several Vermillion directors have agreed to purchase ... common stock and warrants to purchase unregistered shares ... Under the terms of the ...
(Date:12/24/2014)... SARASOTA, Fla. , Dec. 23, 2014  Rock ... today that it has filed a Clinical Trial Application ... Medicines Healthcare products Regulatory Agency (MHRA) seeking regulatory approval ... its lead molecule, Anatabine Citrate. Contingent on ... to conduct a Phase I trial to assess the ...
(Date:12/22/2014)... 2014   Synthetic Biologics, Inc. ... therapies for serious infections and diseases, with ... announced positive topline safety and tolerability results ... SYN-004, the Company,s investigational oral beta-lactamase enzyme ... (C. difficile) infection, antibiotic-associated diarrhea and ...
Breaking Biology Technology:The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5
... May 7 The Sixth Annual Healthcare Unbound Conference ... (TCBI), will feature the coming together of consumer and ... The Conference will take place at the ... 2009. Attendees will include a diverse representation of ...
... May 7 /PRNewswire-FirstCall/ -- Delcath Systems, Inc., ... technology company testing its proprietary Percutaneous Hepatic Perfusion (PHP(TM)) System ... that Eric D. Whitman, MD, Director of the Atlantic Melanoma ... will present at The 7th World Congress on Melanoma, to ...
... Parma Group has reacquired the,marketing rights to its own ... of the American pharmaceutical company Cornerstone; it will,be setting ... market. This presence in the USA will prepare the ... of respiratory illnesses. , The ...
Cached Biology Technology:Sixth Annual Healthcare Unbound Conference to Focus on Remote Monitoring, Home Telehealth & eHealth for Chronic Care Management & Wellness Promotion 2Sixth Annual Healthcare Unbound Conference to Focus on Remote Monitoring, Home Telehealth & eHealth for Chronic Care Management & Wellness Promotion 3Eric D. Whitman, MD to Present on the Delcath PHP System(TM) at the 7th World Congress on Melanoma 2Eric D. Whitman, MD to Present on the Delcath PHP System(TM) at the 7th World Congress on Melanoma 3The Chiesi Group Lands in the United States 2The Chiesi Group Lands in the United States 3
Antibodies were affinity purified using epitopes specific to Alpha4 immobilized on solid support....
PlusOne Acrylamide PAGE, 1 kg. Category: Electrophoresis Systems & Standards & Reagents, Electrophoresis Standards and Reagents, Gel Casting Chemicals....
Donor Horse Serum US Origin...
jub, ajuba homolog (Xenopus laevis)...
Biology Products: